The Commission for the Protection of Competition received a notification of a proposed concentration regarding the acquisition of part of the share capital of Pharmathen SA by BC Partners Ltd.
BC Partners Ltd comprises of a number of separate limited partnerships, duly registered in England and Wales. Each limited partnership consists of a number of limited partners and a general partner. The general partners have the control over the BC Funds. Aenova Holding Gmbh is among the holding companies of BC Funds, and it is active in the field of development and production on the basis of contract "CDMO" in pharmaceutical and healthcare products, and in particular the mechanisms of administration by oral solid dosage (oral solid dosage delivery mechanisms). Specifically, Aenova Holding Gmbh provides development services, manufacturing, packaging, transportation, distribution and related services for drugs and dietary supplements. In addition, it provides services associated with mechanisms for granting solid, semi-solid and liquid dosage. The acquisition will be implemented through the holding company Pharmathen Global Ltd, which was created by BC Partners Ltd.
Pharmathen SA is a company duly registered under the laws of Greece and is active in the development, production and the granting of rights of use of complex generic medicines, especially in the market "CDMO"